Abbott: Q3 in line with expectations

(CercleFinance.com) - Abbott Laboratories has posted Q3 adjusted EPS from continuing operations that is up 12% at 84 cents, in line with the consensus, and says it is "right on track to achieve.
.. the upper-end of our initial guidance ranges for the year".

Its revenues increased by 5.5% to 8.08 billion dollars, with organic growth of 7.6% that was led by its medical equipment business (+10.6%) - in particular those for heart attacks (+22.2%) and diabetes (+29.6%).

Abbott says that it now expects FY 2019 adjusted EPS of between 3.23 dollars and 3.25 dollars, hence tightening up its previous target range of 3.21 dollars to 3.27 dollars, implying average expected growth of 12.5% compared to 2018.


Copyright (c) 2019 CercleFinance.com. All rights reserved.